Bioequivalence and Bioavailability Forum

jag009 ★★★ NJ, 2018-09-07 22:31 (2852 d 19:38 ago) Posting: # 19251 Views: 3,807	FDA Supac guidance for ER [Regulatives / Guidelines] Post reply
	Hi, Question. To support SUPAC (post approval manufacturing site change) filing for ER products, do we need to perform multimedia dissolution testings? Thanks John

Helmut
★★★

Vienna, Austria,
2018-09-09 16:04
(2851 d 02:05 ago)

@ jag009
Posting: # 19253
Views: 3,077

FDA Supac guidance for ER

Post reply

Hi John,

❝ To support SUPAC (post approval manufacturing site change) filing for ER products, do we need to perform multimedia dissolution testings?

Generally not. That’s a Level 3 Change.
See the guidance V. C. 2. b. Dissolution documentation:

In addition to application/compendial release requirements, a multipoint dissolution profile should be obtained using application/compendial test conditions for the changed drug product and the biobatch or marketed batch (unchanged drug product). Adequate sampling should be performed, for example at 1, 2, and 4 hours and every two hours thereafter until either 80% of the drug from the drug product is released or an asymptote is reached.

But don’t forget V. C. 2. c. Bioequivalence documentation:

A single-dose bioequivalence study. The bioequivalence study may be waived in the presence of an established in vitro/in vivo correlation.

—
Dif-tor heh smusma 🖖🏼 Довге життя Україна!
Helmut Schütz

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

jag009 ★★★ NJ, 2018-09-10 20:38 (2849 d 21:31 ago) @ Helmut Posting: # 19256 Views: 3,014	FDA Supac guidance for ER Post reply
	Thank Helmut!

FDA Supac guidance for ER [Regulatives / Guidelines]

FDA Supac guidance for ER

FDA Supac guidance for ER